chapter 3
Introduction to Psychotropic Drug Targets
Major Classes of Targets:
Twelve-transmembrane region transporter: ~30% of psychotropic drugs.
Seven-transmembrane region G-protein linked receptor: ~30% of psychotropic drugs.
Enzyme: ~10% of psychotropic drugs.
Four-transmembrane region ligand-gated ion channel: ~20% of psychotropic drugs.
Six-transmembrane region voltage-gated ion channel: ~10% of psychotropic drugs.
Ligand-Gated Ion Channels
Key Ligand-Gated Ion Channels Directly Targeted by Psychotropic Drugs:
Neurotransmitter: Acetylcholine
Receptor subtype: α4β2-nicotinic receptors
Pharmacological action: Partial agonist
Therapeutic action: Smoking cessation.
Neurotransmitter: GABA
Receptor subtype: GABA-A benzodiazepine receptors
Pharmacological action: Full agonist, phasic inhibition
Therapeutic action: Anxiolytic.
GABA-A non-benzodiazepine PAM sites
Pharmacological action: Full agonist, phasic inhibition
Therapeutic action: Improves insomnia.
GABA-A neurosteroid sites (benzodiazepine insensitive)
Pharmacological action: Full agonist, tonic inhibition
Therapeutic action: Post-partum depression, Rapid-acting antidepressant, Anesthetic.
Neurotransmitter: Glutamate
Receptor subtype: NMDA NAM channels sites/Mg²⁺ sites
Pharmacological action: Antagonist
Therapeutic action: Procognitive in Alzheimer disease.
NMDA open channel sites
Pharmacological action: Antagonist
Therapeutic action: Dissociative hallucinogen, Anesthetic, Pseudobulbar affect, Agitation in Alzheimer disease, Rapid-acting antidepressant, Treatment-resistant depression.
Neurotransmitter: Serotonin
Receptor subtype: 5HT3
Pharmacological action: Antagonist
Therapeutic action: Procognitive, Antidepressant, Reduce chemotherapy-induced emesis.
Structurally Diverse Channels
Pentameric Ligand-Gated Ion Channels (pLGICs)
Subtypes include:
Nicotinic acetylcholine (nAChR)
Type 3 serotonin (5-HT3R)
GABA type A (GABAAR)
Glycine receptors (GlyR)
Structure: Comprised of five subunits arranged around a central pore, allowing ion fluxes that modify the membrane potential and neuronal excitability.
Conserved Architecture: Recent structural data shows a cylinder-shape, with:
Extracellular domain (ECD): Contains the agonist-binding site.
Four transmembrane domains (TM1–4): Shape the ion pore.
Large intracellular domain (ICD): Between TM3 and TM4.
Short extracellular C-terminal region.
Tetrameric Ligand-Gated Ion Channels (Ionotropic Glutamate Receptors)
Examples:
Glutamate receptors: AMPA (GluR1–4 subunits), KAINATE (GluR5–7, KA1–2 subunits), NMDA (NMDAR1, NMDAR2A–D, NMDAR3A subunits).
Structure: Consists of 3 transmembrane regions, 1 re-entrant loop, and 4 subunits.
Implications: Involved in nervous system development; dysfunction linked to diseases like Alzheimer’s, Parkinson’s, schizophrenia, depression, brain trauma, and stroke.
Agonist and Antagonist Interaction
The Agonist Spectrum
Agonist: Naturally activates the channel.
Partial agonist: Binds to the receptor but causes lesser activation than a full agonist.
Antagonist: Binds to the receptor but does not activate it. Can stabilize the channel into a resting state.
Inverse agonist: Stabilizes the channel in an inactive form by reducing the channel's activity further than the baseline.
Receptor Desensitization
Desensitization Process: Prolonged exposure to an agonist can lead to desensitization characterized by:
Uncoupling: Occurs within seconds to minutes after agonist application.
Internalization: Decreased receptor density in response to continual stimulation (minutes).
Downregulation/Degradation: Decrease of receptor availability (hours to days).
Positive and Negative Allosteric Modulators (PAMs and NAMs)
Positive Allosteric Modulator (PAM)
Mechanism: Enhances the effect of the agonist, leading to greater ion influx when both agonist and PAM are present.
Example: Benzodiazepines (e.g., Valium) enhance GABA-A receptor activity, useful for anxiety and insomnia.
GABA-A Receptor Activation: When GABA binds to its site, the channel opens and allows chloride ions (Cl⁻) into the cell, leading to hyperpolarization and reduced excitability.
Negative Allosteric Modulator (NAM)
Mechanism: Reduces the efficacy of the agonist, leading to decreased ion conductance when both agonist and NAM are present.
Example: Flumazenil is a NAM at the benzodiazepine site on GABA-A receptors, used to counteract benzodiazepine overdoses.
Action Potentials and Ion Channel Function
Ionic Components of an Action Potential:
Sodium (Na⁺)
Calcium (Ca²⁺)
Potassium (K⁺)
Voltage-Sensitive Sodium Channel (VSSC) States:
Open: Allows Na⁺ influx.
Inactivated: Channel cannot open; resets the channel.
Closed: The channel is in a resting state but can open again.
Function of Voltage-Sensitive Calcium Channels (VSCCs): Trigger neurotransmitter release upon activation during action potentials.
Dysregulation and Neurological Disorders
Consequences of Dysregulation: Alterations in calcium channel activity can lead to neurological disorders including:
Epilepsy
Migraine
Chronic pain
Importance of Voltage-Gated Calcium Channels: They are pharmacological targets for these neurological conditions due to their role in neurotransmitter release and neuronal excitability regulation.
Summary of Voltage-Sensitive Calcium Channels (VSCCs)
Types of VSCCs and Their Functions:
L Type (Cav 1.2, 1.3): Gene expression, synaptic integration.
N Type (Cav 2.2): Transmitter release, synaptic integration.
P/Q Type (Cav 2.1): Transmitter release, synaptic integration.
R Type (Cav 2.3): Transmitter release, synaptic integration.
T Type (Cav 3.1, 3.2, 3.3): Pacemaking, repetitive firing, synaptic integration.